Last reviewed 2026-04-19 · How we verify

[131I]-SGMIB Anti-HER2 VHH1

Precirix · Phase 1 active Biologic

[131I]-SGMIB Anti-HER2 VHH1 is a Biologic drug developed by Precirix. It is currently in Phase 1 development.

At a glance

Generic name	[131I]-SGMIB Anti-HER2 VHH1
Sponsor	Precirix
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[131I]-SGMIB Anti-HER2 VHH1 CI brief — competitive landscape report
[131I]-SGMIB Anti-HER2 VHH1 updates RSS · CI watch RSS
Precirix portfolio CI

Frequently asked questions about [131I]-SGMIB Anti-HER2 VHH1

What is [131I]-SGMIB Anti-HER2 VHH1?

[131I]-SGMIB Anti-HER2 VHH1 is a Biologic drug developed by Precirix.

Who makes [131I]-SGMIB Anti-HER2 VHH1?

[131I]-SGMIB Anti-HER2 VHH1 is developed by Precirix (see full Precirix pipeline at /company/precirix).

What development phase is [131I]-SGMIB Anti-HER2 VHH1 in?

[131I]-SGMIB Anti-HER2 VHH1 is in Phase 1.

Manufacturer: Precirix — full pipeline
Compare: [131I]-SGMIB Anti-HER2 VHH1 vs similar drugs
Pricing: [131I]-SGMIB Anti-HER2 VHH1 cost, discount & access